Business Wire

HSBC Continental Europe1 Interim Results 2022 

14.9.2022 17:46:00 EEST | Business Wire | Press release

Share

On 29 July 2022, HSBC Continental Europe’s Board of Directors approved the bank’s consolidated financial statements for the first half of 2022.

HSBC Continental Europe’s performance during the first half of 2022 was positive with continued profitability driven by growth in wholesale banking revenues, demonstrating the strength of our global franchise and international connectivity, coupled with low credit losses and a favourable cost performance. With inflationary pressure across Europe and the ongoing Russia-Ukraine war, we expect to be operating in a more difficult environment for the remainder of the year.

Reported consolidated profit before tax was €184m, down from €187m in the first half of 2021, and included an exceptional loss and related impairments of €111m recognised in relation to the planned sale of HSBC Continental Europe’s operations in Greece.

Reported net operating income before change in expected credit losses and other credit impairment charges was €1,218m, down from €1,296m in the first half of 2021, including the exceptional loss recognised in relation to the planned sale of the operations in Greece and a less favourable PVIF movement – €123m in the first half of 2022, compared with a favourable movement of €171m in the first half of 2021. These impacts were largely offset by growth in Commercial Banking and Global Banking, which benefitted from increased client activity and rising interest rates. In addition, Markets and Securities Services revenues increased due to higher transaction volumes, notably in Global Foreign Exchange and Securities Services.

Reported change in expected credit losses and other credit impairment charges was nil, compared to a release of €1m in the first half of 2021. The deterioration of forward-looking economic conditions driven by the rising risk of stagflation and disruption to energy supply was offset by the release of Stage 3 provisions.

Reported operating expenses were €1,034m, down from €1,111m in the first half of 2021. The decrease was due to the recognition of a recovery of VAT paid in 2021 and lower staff costs, partly offset by transformation related costs.

Reported profit attributable to shareholders of the parent company was €127m for the half year to 30 June 2022, compared with €153m in the first half of 2021.

The consolidated balance sheet of HSBC Continental Europe showed total assets of €239bn at 30 June 2022, compared to €223bn at 31 December 2021 with the increase mainly driven by mark-to-market movements on derivatives.

At 30 June 2022, HSBC Continental Europe reported a liquidity coverage ratio (LCR)2 of 145% and a net stable funding ratio (NSFR)3 of 129%. The bank’s fully loaded common equity tier 1 (CET1) ratio was 13.7% and the fully loaded total capital ratio was 18.7% The fully loaded leverage ratio was 3.9%. The solvency ratio of the Life Insurance subsidiary was 263%4.

Planned sale of Greece branch operations and retail banking business in France

Our business transformation has continued to progress at pace, with the signing of a sale and purchase agreement for the sale of our branch operations in Greece to Pancreta Bank SA on 24 May 2022. This followed the completion of the works council consultations. Completion of the potential transaction is subject to regulatory approval and is currently expected to finalise towards the end of the first half of 2023.

As at 30 June 2022, €2.1bn in total assets, including €0.4bn of customer loan balances and €2.3bn in total liabilities, including €2.2bn of customer accounts were reclassified as held for sale in accordance with IFRS 5 and losses and impairments of €111m were recognised for the planned sale of Greece branch operations.

As previously disclosed, we remain on track to complete the sale of our retail banking business in France in the second half of 2023.

Appendix

Interim accounts were subject to a limited review by the statutory auditors.

Summary consolidated income statement

€m

Half year to
30 June 2022

Half year to
30 June 2021

Half year to
31 Dec 2021

Net interest income

556

480

507

Net fee income

485

457

458

Net income/(expense) from financial instruments held for trading or managed on a fair value basis

211

90

(9)

Other operating income/(expense)

(34)

269

111

Net operating income before change in expected credit losses and other credit impairment charges

1,218

1,296

1,067

Change in expected credit losses and other credit impairment charges

—

1

(34)

Total operating expenses

(1,034)

(1,111)

(935)

Share of profit in associates and joint ventures

—

1

—

Profit/(loss) before tax

184

187

98

Tax expense

(57)

(34)

17

Profit/(loss) for the period

127

153

115

Profit/(loss) attributable to shareholders of the parent company

127

153

116

Profit/(loss) attributable to non-controlling interests

—

—

(1)

PVIF (Present value of in force long-term insurance business)

HSBC Continental Europe, through its HSBC Assurances Vie subsidiary, accounts for its life insurance business using the embedded value method, which provides a comprehensive framework for assessing risk and valuation. PVIF (present value of in force long-term insurance business) is the present value of future profits from existing insurance policies.

The PVIF calculation is based on assumptions that take into account business risks and uncertainties. When projecting cash flows, HSBC Assurances Vie makes a series of assumptions regarding future experience, taking into account local market conditions and management’s judgment of future local trends.

In the first half of 2022, the PVIF movement was favourable by €123m, compared to €171m in the first half of 2021.

Post-balance sheet events

On 20 July 2022, the Board of Directors convened an Extraordinary General Meeting to be held on 2 September 2022 to propose a share capital increase of €1,300m, related to the planned sale of the retail banking business in France.

Alternative performance metrics

To measure our performance, we also use non-GAAP financial measures, including those derived from our reported results that eliminate factors that distort year-on-year comparisons. The ‘adjusted performance’ measure removes the impact of ‘significant items’, listed below, and year-on-year foreign currency translation differences.

 

€m

Half year to

30 June 2022

Half year to

30 June 2021

Half year to

31 Dec 2021

Reported revenue

1,218

1,296

1,067

Significant revenue items

93

26

129

Adjusted revenue

1,311

1,322

1,196

 

 

 

 

Reported operating expenses

(1,034)

(1,111)

(935)

Significant cost items

75

30

61

– Impairment of goodwill, intangibles and tangibles

8

(1)

3

– Restructuring cost and other significant items

67

31

58

Adjusted operating expenses

(959)

(1,081)

(874)

Adjusted results by business line

HSBC Continental Europe changed its segmental reporting in the second half of 2021 by splitting the business line ‘Global Banking and Markets’ into three business lines: ‘Markets and Securities Services’, ‘Global Banking’ and ‘Global Banking and Markets Other’. Financials for the first half of 2021 were re-presented accordingly with no impact on the consolidated financial results.

 

 

Wealth and
Personal
Banking

Commercial
Banking

Markets and
Securities
Services

Global
Banking

Global Banking
and Markets
Other

Corporate
Centre

Total

 

 

 

 

 

 

 

 

€m

Half year to 30 June 2022

Net operating income before change in expected credit losses and other credit impairment charges

467

410

179

251

27

(23)

1,311

Change in expected credit losses and other credit impairment charges

(2)

11

—

(10)

1

—

—

Total operating expenses

(361)

(215)

(201)

(140)

(31)

(11)

(959)

Share of profit in associates and joint ventures

—

—

—

—

—

—

—

Adjusted profit/(loss) before tax

104

206

(22)

101

(3)

(34)

352

 

 

Half year to 30 June 2021

Net operating income before change in expected credit losses and other credit impairment charges

544

363

157

224

30

4

1,322

Change in expected credit losses and other credit impairment charges

10

(33)

—

24

—

—

1

Total operating expenses

(397)

(254)

(230)

(137)

(31)

(32)

(1,081)

Share of profit in associates and joint ventures

—

—

—

—

—

1

1

Adjusted profit/(loss) before tax

157

76

(73)

111

(1)

(27)

243

 

 

 

 

 

 

 

 

 

Half year to 31 December 2021

Net operating income before change in expected credit losses and other credit impairment charges

394

362

103

279

40

18

1,196

Change in expected credit losses and other credit impairment charges

10

(35)

—

(11)

2

—

(34)

Total operating expenses

(363)

(181)

(146)

(123)

(33)

(28)

(874)

Share of profit in associates and joint ventures

—

—

—

—

—

—

—

Adjusted profit/(loss) before tax

41

146

(43)

145

9

(10)

288

HSBC Continental Europe

Headquartered in Paris, HSBC Continental Europe is a subsidiary of HSBC Holdings plc. HSBC Continental Europe includes, in addition to its activities in France, the activities of 10 European branches (Belgium, Czech Republic, Greece, Ireland, Italy, Luxembourg, Netherlands, Poland, Spain and Sweden). HSBC Continental Europe’s mission is to serve customers in continental Europe for their needs worldwide and customers in other Group countries for their needs in continental Europe.

HSBC Holdings plc

HSBC Holdings plc, the parent company of HSBC, is headquartered in London. HSBC serves customers worldwide from offices in 63 countries and territories in its geographical regions: Europe, Asia, North America, Latin America, and Middle East and North Africa. With assets of US$2,985bn at 30 June 2022, HSBC is one of the world’s largest banking and financial services organisations.

Disclaimer

This press release contains certain forward-looking statements with respect to the financial condition, results of operations and business of the entity. Statements that are not historical facts, including statements about the entity’s beliefs and expectations, are forward-looking statements. Words such as ‘expects’, ‘anticipates’, ‘intends’, ‘plans’, ‘believes’, ‘seeks’, ‘estimates’, ‘potential’ and ‘reasonably possible’, variations of these words and similar expressions are intended to identify forward-looking statements. These statements are based on current plans, estimates and projections, and therefore undue reliance should not be placed on them. Forward-looking statements speak only as of the date they are made. HSBC Continental Europe makes no commitment to revise or update any forward-looking statements to reflect events or circumstances occurring or existing after the date of any forward-looking statement. Forward-looking statements involve inherent risks and uncertainties. Readers are cautioned that a number of factors could cause actual results to differ, in some instances materially, from those anticipated or implied in any forward-looking statements.

1 HSBC Continental Europe includes, in addition to its activities in France, the activities of 10 European branches (Belgium, Czech Republic, Greece, Ireland, Italy, Luxembourg, Netherlands, Poland, Spain and Sweden)
2 Computed in respect of the EU Delegated act
3 Computed in respect of CRR II (Regulation EU 2019/876)
4 LCR, NSFR and the solvency ratio of the Life Assurance subsidiary are unaudited

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Raphaële-Marie Hirsch
raphaele.marie.hirsch@hsbc.fr
07 64 57 35 55

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo ® ) in Patients With Mycosis Fungoides and Sézary Syndrome12.10.2026 09:00:00 EEST | Press release

Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides (MF) and Sézary Syndrome (SS). Presented at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) Annual Meeting 2026 in Berlin, Germany, the findings represent one of the largest real-world evaluations of mogamulizumab in Germany and add to the growing body of evidence supporting its use in routine clinical practice.1-3 Conducted as a company-sponsored, multicentric, non-interventional, combined retro-prospective real-world study across 18 centres throughout Germany, MINT brought together cutaneous T‑cell lymphoma (CTCL) specialists to evaluate treatment outcomes with mogamulizumab in a real-world setting, with time-to-next-treatment (TTNT) as the study’s primary endpoint.1 The study captured a broad and heterog

Megaport Expands Global Automated Infrastructure Platform Into Portugal12.10.2026 09:00:00 EEST | Press release

Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of its services in Portugal, expanding its European footprint and enabling enterprises and service providers in the region to connect instantly to the world’s leading cloud, network, and data center providers. With new on-ramps in Lisbon, customers in Portugal can now access Megaport’s automated infrastructure platform as well as more than 1,200 enabled data centers worldwide. This launch gives enterprises, MSPs, and carriers private, high-performance compute, network, and storage, as well as on-demand regional interconnection with scalable bandwidth. With Portugal’s data center market projected to reach US$3.09 billion by 2030 as well as Lisbon’s proximity to major submarine cable landings, the strengthening global connectivity hub is a natural next step for Megaport. “Portugal’s digital economy is rapidly growing, and infrastructure is at the heart of that transfor

Filippo Fagnani from Quanta System Receives the EAU Award for Significant Contribution to Endourology at ICE 202610.10.2026 19:09:00 EEST | Press release

Filippo Fagnani, Marketing & Scientific Director of Quanta System’s Surgical Division, has been honoured with the Award for Significant Contribution to Endourology at ICE26, the International Conference on Endourology organised by the EAU Endourology Section. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010101303/en/ Filippo Fagnani receiving the prize with Olivier Traxer and Professor Bhaskar Somani. The recognition celebrates more than two decades of professional commitment to laser technology and a career built around a clear ambition: to translate the needs of urologists into increasingly precise, flexible and useful technologies, with the ultimate goal of supporting patient safety and better surgical outcomes. “I have always believed that technology should make the surgeon’s work more precise, more flexible and, most importantly, safer for the patient. My goal has never been to develop technology for its own sake,

Emdoor Information Marks 18 Years of Rugged Computing Excellence with Vertically Integrated Capabilities10.10.2026 13:30:00 EEST | Press release

As industrial automation, smart manufacturing, and field operations increasingly depend on mission-critical mobile computing, global demand for reliable rugged tablets, rugged laptops, and rugged handhelds continues to accelerate. Emdoor Information, a publicly listed company on China’s A-share main board since 2023 and an 18-year veteran in rugged computing, has established itself as a rugged computing solutions provider for industrial customers worldwide. Founded in 2008, the company delivers sustained growth, world-class manufacturing, resilient supply chains, full-stack R&D, and comprehensive lifecycle services. Its rugged computing products and industrial customers now span North America, Latin America, Europe, and Asia-Pacific, serving sectors such as public utilities, intelligent manufacturing, warehouse management, transportation, energy industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010564561/en/ Rugged

Vertex to Present New Data on ALYFTREK ® at the North American Cystic Fibrosis Conference9.10.2026 20:15:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine pancreatic function represent a profound shift in how we understand the benefits of treating cystic fibrosis in its earliest stages,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Devel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye